OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
04/23/2026
Back to search
Official data from USPTO
PHARMACOSMOS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
PHARMACOSMOS
ST13
US500000079363592Class
1, 5, 42
Filing
79363592
Registration
7431033
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
30
Latest update
04/24/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
11/28/2022
Registration date
07/02/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/02/2024
Last transaction
04/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
65
Owner location
DK
Examiner
MESSICK, TABITHA LEE
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Pharmacosmos Holding A/S
Representatives
Shannon Marie McKeon Dykema Gossett PLLC
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Glucose for industrial purposes; glucose derivatives for industrial purposes; glucose oligo- and polysaccharides for industrial purposes; dextran being glucose for industrial purposes; dextran derivatives being glucose for industrial purposes; industrial chemicalsexcipientscryoprotectantslyoprotectants and media for use in storingfreezinggrowing and thawing of humanplant or animal cells or tissue for non-medical purposes; industrial chemicalsexcipientscryoprotectantslyoprotectants and media in the nature of carbohydrates or carbohydrate derivativesglucoseglucose derivativesglucose oligo- and polysaccharidesdextranand/or dextran derivativesoligosaccharidespolysaccharidesderivatives of oligosaccharides and polysaccharidesglucose oligosaccharidesglucose polysaccharidesderivatives of glucose oligosaccharides and glucose polysaccharidesnanomoleculesiron nano moleculespolynuclear iron carbohydrate complexesiron oligosaccharides complexesiron polysaccharide complexesiron chelatorswritten transfection agentsin solidliquid or gaseous state for use in storingfreezinggrowing and thawing of humanplant or animal cells or tissue for non-medical purposes; industrial chemicalsexcipientscryoprotectantslyoprotectants and media in the nature of non-carbohydrates in solidliquid or gaseous state for use in storingfreezinggrowing and thawing of humanplant or animal cells or tissue for non-medical purposes; chemicals for use as excipientscryoprotectantslyoprotectants and media in the manufacture of pharmaceuticals; biological tissue cultures other than for medical or veterinary purposes; chemicals for use in the manufacture of cosmetics; chemicals for use in the manufacture of food supplements; industrial chemicalscarbohydrates or carbohydrate derivativesglucoseglucose derivativesglucose oligo- and/or polysaccharidesdextrandextran derivatives for use in chromatographyseparation systemsmolecular weight measurementslyophilizationcell mediatransfectionindustrial applications; nanopowders for industrial purposes; industrial chemicalsexcipientscryoprotectantslyoprotectants and media for use in storinggrowingfreezing and thawing of humanplant or animal cells or tissue for research purposes
Class 5
Pharmaceutical preparations for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload in humans; veterinary preparations for the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload in animals; dietary supplements for human beings and animals; dietetic food and substancesbeverages adapted for medical and veterinary purposes; diagnostic preparations for medical and veterinary purposes; molecular weight testing reagents for diagnostic purposes; medicalpharmaceutical and veterinary preparations for parenteral administrationin particular oralintravenousintramuscular and subcutaneousfor the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; iron preparations for pharmaceutical and veterinary use in the nature of dietary supplements consisting primarily of iron; iron preparations as food supplements; glucose for medical purposes; diagnostic agentspreparations and substances for medical purposesexcipientscryoprotectantslyoprotectants and media for use in storinggrowingfreezing and thawing of humanplant or animal cells or tissue for medical or veterinary purposesnot for manufacturing; diagnostic agentspreparations and substances for medical purposesexcipientscryoprotectantslyoprotectants and media in the nature of carbohydrates in solidliquid or gaseous state for use in storingfreezinggrowing and thawing of humanplant or animal cells or tissue for medical or veterinary purposes not for manufacturing; diagnostic agentspreparations and substances for medical purposesexcipientscryoprotectantslyoprotectants and media in the nature of non-carbohydrates in solidliquid or gaseous state for use in storingfreezinggrowing and/or thawing of humanplant or animal cells or tissue for medical or veterinary purposes not for manufacturing; biological tissue cultures for medical and veterinary purposes; chemical preparations for medical and pharmaceutical purposesfor the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; chemical preparations for veterinary purposesfor the treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; chemical reagents for medical or veterinary purposes
Class 42
Scientific research for medicalveterinary and chemical purposes; scientific research in the nature of conducting clinical trials in the field of treatment and/or prevention of iron deficiency and/or anaemia or of iron overload; scientific research for medical and chemical purposes in the field of storingfreezinggrowing and/or thawing biological materialcellscancer cells and stem cells; providing medical and scientific research information relating to pharmaceuticals and clinical trials; molecular weight testing services for scientific research purposes
Publications
History of USPTO decisions and trademark events.
30 publications found
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/06/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
04/06/2026
CORR
CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
03/11/2025
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
11/08/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/02/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/02/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/16/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/16/2024
PUBO
PUBLISHED FOR OPPOSITION
04/16/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/27/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/27/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/27/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/08/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/13/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/13/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/13/2024
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
01/05/2024
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
12/17/2023
RFNT
REFUSAL PROCESSED BY IB
09/13/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/19/2023
RFRR
REFUSAL PROCESSED BY MPU
08/19/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/26/2023
CNRT
NON-FINAL ACTION WRITTEN
07/25/2023
DOCK
ASSIGNED TO EXAMINER
07/18/2023
MAFR
APPLICATION FILING RECEIPT MAILED
03/17/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/13/2023
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
03/03/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/23/2023
Continuous trademark protection
Get notified about every new filing that threatens PHARMACOSMOS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.